Testing Becotatug Vedotin ± Immunotherapy for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or spreading esophageal squamous cell cancer that has not responded to or stopped working after at least one previous treatment, including an immunotherapy drug.
- Your tumor has a protein called EGFR (found in a lab test).
- You are 18 or older, willing to sign a consent form, and expected to live at least 12 more weeks.
- You have at least one tumor that can be measured on a scan (not in the brain) and can provide a tissue sample from a recent biopsy or surgery.
- You are generally in good health (able to do daily activities, no serious heart or lung problems, and acceptable blood counts and kidney/liver function).
- You agree to use effective birth control during the study and for 6 months after the last dose (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for advanced esophageal squamous cell carcinoma that has stopped responding to prior treatment. The goal is to see if the combination can shrink tumors and help patients live longer.
This trial tests a new drug (Becotatug Vedotin) combined with standard chemotherapy and radiation for locally advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial tests a precision medicine approach for people with advanced esophageal cancer that has stopped responding to immunotherapy. The goal is to find better treatments based on each person's tumor biology.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.